Kairos Pharma Ltd. (NYSE American: KAPA) announced that its CEO and Chairman Dr. John Yu is scheduled to present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT in Los Angeles. The presentation will provide an update on the company’s clinical program and partnering activities, offering investors insight into the progress of its lead oncology candidate.
The company, based in Los Angeles, focuses on oncology therapeutics using structural biology to overcome drug resistance and immune suppression. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. The company notes that ENV-105 has not yet been approved as safe or effective by the U.S. Food and Drug Administration or any comparable foreign regulator.
The LD Micro Invitational is a key industry event that provides a platform for emerging growth companies to present to a broad audience of investors. Dr. Yu’s presentation will likely focus on clinical data updates and partnership discussions that could shape Kairos Pharma’s trajectory. The announcement underscores the company’s commitment to advancing its pipeline and seeking strategic collaborations.
For more details on Kairos Pharma and its latest news, the company’s newsroom can be accessed at https://ibn.fm/KAPA. The full press release regarding the presentation is available at https://ibn.fm/g3aQY.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress and Partnership Efforts.